Evidence map›Paper›PMID 40093677›Full record

ReviewWorld journal of gastroenterology2025

Advances in imaging techniques for tumor microenvironment evaluation in hepatocellular carcinoma.

Li-Li Wang, Fa-Chang Zhang, Han-Xin Xu, Dian-Dian Deng, Bing-Jie Ren, Qi Tan, Ya-Xin Liu, Wen-Hui Zhao, Jia-Le Lu

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Li-Li WangDepartment of Radiology, The First Hospital of Lanzhou University, Lanzhou 730030, Gansu Province, China. wangll19@lzu.edu.cn.
Fa-Chang ZhangFirst Clinical Medical School of Lanzhou University, Lanzhou University, Lanzhou 730030, Gansu Province, China.
Han-Xin XuFirst Clinical Medical School of Lanzhou University, Lanzhou University, Lanzhou 730030, Gansu Province, China.
Dian-Dian DengFirst Clinical Medical School of Lanzhou University, Lanzhou University, Lanzhou 730030, Gansu Province, China.
Bing-Jie RenFirst Clinical Medical School of Lanzhou University, Lanzhou University, Lanzhou 730030, Gansu Province, China.
Qi TanFirst Clinical Medical School of Lanzhou University, Lanzhou University, Lanzhou 730030, Gansu Province, China.
Ya-Xin LiuFirst Clinical Medical School of Lanzhou University, Lanzhou University, Lanzhou 730030, Gansu Province, China.
Wen-Hui ZhaoFirst Clinical Medical School of Lanzhou University, Lanzhou University, Lanzhou 730030, Gansu Province, China.
Jia-Le LuFirst Clinical Medical School of Lanzhou University, Lanzhou University, Lanzhou 730030, Gansu Province, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The tumor microenvironment (TME) plays a critical role in the development and treatment of liver cancer, which ranks sixth in incidence and third in mortality worldwide, according to the "Global Cancer Statistics 2022". Hepatocellular carcinoma (HCC), the most common form of liver cancer, is heavily influenced by the TME, which affects tumor growth, invasion, metastasis, and the response to various treatments. Despite advancements in surgery, liver transplantation, targeted therapies, and immunotherapy, the complexity of the TME often limits treatment efficacy, especially in advanced-stage HCC cases. The TME consists of a dynamic interaction between tumor cells, immune cells, fibroblasts, blood vessels, and signaling molecules, all of which contribute to cancer progression and therapy resistance. Assessing the HCC TME is essential for designing effective, personalized treatments and improving patient outcomes. Recent research highlights the value of imaging technologies as non-invasive tools to evaluate the TME, offering new possibilities for more targeted therapies and better prognosis monitoring in HCC patients.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsTumor MicroenvironmentDisease ProgressionHumansLiverPrognosisHepatocellular carcinomaImaging diagnosisMolecular imagingNon-invasive assessmentTumor microenvironment

Identifiers

PMID40093677
PMCPMC11886532

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.